Amoxicillin outperforms penicillin V in treating pediatric pneumonia, study finds

FHS
June 18, 2024
5:29 am

A recent study confirmed amoxicillin’s lower risk of treatment failure compared to penicillin V in treating pediatric pneumonia, with no difference in severe complications.

Is there room for MASH drugs in a GLP-1 world?

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 5, 2024

Kevin Tang’s Concentra swoops in on another struggling biotech, offering to buy Kezar

Concentra Biosciences, a shell company from Tang Capital, wants to buy another biotech that has found itself in a bind. Kevin Tang’s shop told Kezar

October 10, 2024

Bioengineered nanovesicles could improve cancer treatment

Nanovesicles can be bioengineered to target cancer cells and deliver treatments directly, according to research at Binghamton University, State University of New York.

August 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.